Roth Capital Starts Verastem (VSTM) at Buy
Tweet
Share
E-mailGet Alerts VSTM Hot Sheet
Rating Summary:
16 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Roth Capital initiates coverage on Verastem (NASDAQ: VSTM) with a Buy rating and a price target of $12.00.
Analyst Jotin Marango is bullish on the company ahead of CLL data at the ASH conference next week and ahead of the NDA filing for CLL and FL in Q1 2018. The analyst focuses on the in-licensed oral PI3K inhibitor duvelisib which, when stripped of fatiguing corporate past, is an NDA-ready asset unblocking value in excess of Verastem's current $150 milliom MC.
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $3.66 yesterday.
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
